Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
46
OPK Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
6.84%
Day range:
$1.53 - $1.57
52-week range:
$0.85 - $1.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.72x
P/B ratio:
0.74x
Volume:
4.5M
Avg. volume:
5.1M
1-year change:
-0.64%
Market cap:
$1B
Revenue:
$863.5M
EPS (TTM):
-$0.19
Analysts' Opinion
-
Consensus RatingOPKO Health has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, OPKO Health has an estimated upside of 155.38% from its current price of $1.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.55.
Fair Value
-
According to the consensus of 0 analysts, OPKO Health has 155.38% upside to fair value with a price target of -- per share.
OPK vs. S&P 500
-
Over the past 5 trading days, OPKO Health has underperformed the S&P 500 by -0.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
OPKO Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
OPKO Health revenues have been falling on a year-over-year basis for 13 quarters in a row. In the most recent quarter OPKO Health reported revenues of $173.6M.
Earnings Growth
-
OPKO Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter OPKO Health reported earnings per share of $0.03.
Enterprise value:
1.1B
EV / Invested capital:
0.58x
Price / LTM sales:
1.72x
EV / EBIT:
--
EV / Revenue:
1.51x
PEG ratio (5yr expected):
-0.22x
EV / Free cash flow:
-5.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
56.84x
Gross Profit (TTM):
$178.6M
Return On Assets:
-6.51%
Net Income Margin (TTM):
-18.8%
Return On Equity:
-9.71%
Return On Invested Capital:
-7.98%
Operating Margin:
-61.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2B | $866.9M | $711.4M | $178.6M | $173.6M | |
| Gross Profit | $340.7M | $329.4M | $178.6M | $47.7M | $40.1M | |
| Operating Income | -$250.3M | -$148.1M | -$309.5M | -$65.5M | -$107.3M | |
| EBITDA | -$240.7M | -$94.9M | $19M | -$48.7M | $89.9M | |
| Diluted EPS | -$0.44 | -$0.27 | -$0.19 | -$0.11 | $0.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $428.1M | $557.5M | $414M | $357.2M | $629.6M | |
| Total Assets | $2.4B | $2.4B | $2.2B | $2.1B | $2.3B | |
| Current Liabilities | $335.9M | $283M | $267.3M | $200.6M | $211.7M | |
| Total Liabilities | $747.5M | $652.1M | $595.7M | $612.1M | $852.7M | |
| Total Equity | $1.6B | $1.8B | $1.6B | $1.4B | $1.4B | |
| Total Debt | $235.9M | $202.1M | $244.8M | $251.3M | $441M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.2M | -$21.5M | -$177.4M | $33.1M | -$77.1M | |
| Cash From Investing | $90.2M | -$24.7M | $234.8M | -$3.6M | $247.8M | |
| Cash From Financing | $13.7M | $2.6M | $220.9M | $2.1M | $206.1M | |
| Free Cash Flow | -$94.2M | -$41.1M | -$200M | $28.9M | -$85M | |
OPK
Sector
Market Cap
$1B
$44.6M
Price % of 52-Week High
88.07%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-0.64%
-29.09%
Beta (5-Year)
1.616
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.59
200-day SMA
Buy
Level
$1.40
Bollinger Bands (100)
Buy
Level
1.45 - 1.61
Chaikin Money Flow
Sell
Level
-153.1M
20-day SMA
Sell
Level
$1.58
Relative Strength Index (RSI14)
Sell
Level
46.88
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-84
50-day SMA
Buy
Level
$1.54
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
218.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0603)
Buy
CA Score
(Annual)
Level (0.2746)
Buy
Beneish M-Score
(Annual)
Level (-2.9614)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (0.0421)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
Stock Forecast FAQ
In the current month, OPK has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OPK average analyst price target in the past 3 months is --.
-
Where Will OPKO Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that OPKO Health share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About OPKO Health?
Analysts are divided on their view about OPKO Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OPKO Health is a Sell and believe this share price will drop from its current level to --.
-
What Is OPKO Health's Price Target?
The price target for OPKO Health over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OPK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for OPKO Health is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OPK?
You can purchase shares of OPKO Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OPKO Health shares.
-
What Is The OPKO Health Share Price Today?
OPKO Health was last trading at $1.55 per share. This represents the most recent stock quote for OPKO Health. Yesterday, OPKO Health closed at $1.55 per share.
-
How To Buy OPKO Health Stock Online?
In order to purchase OPKO Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
